Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and Bernstein lowered their price targets on the stock, citing concerns over the ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

DexCom reported second quarter earnings and issued guidance after the market closed on Wednesday. The company reported adjusted EPS of 43 cents beating analyst estimates of 39 cents. Get access to the ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...

Dexcom shares sank more than 40% on Friday, their steepest decline ever. The company reported disappointing revenue on Thursday and lowered its full-year guidance. Executives blamed a restructuring of ...

DexCom beat expectations in the third quarter, and it raised its revenue guidance for the full year. Manufacturing issues are putting pressure on margins. For 2026, the company sees growth missing ...

DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the ...